Colin E. Fowler

Colin E. Fowler

Auto-generated profile, based on publicly available information

Colin E. Fowler

The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2018 in eLife
Verified
Journal Article
Open access
Sean FanningSean Fanning
Sean Fanning
RJRinath Jeselsohn
Rinath Jeselsohn
VDVenkatasubramanian Dharmarajan
Venkatasubramanian Dharmarajan
CMChristopher G Mayne
Christopher G Mayne
MKMostafa Karimi
Mostafa Karimi
GGGeoffrey Greene
Geoffrey Greene
Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in the ESR1 (estrogen receptor alpha (ERα)) gene ligand-binding domain (LBD) represent a recognized mechanism of acquired resistance. Antiestrogens with improved efficacy versus tamoxifen might overcome the resistant phenotype in ER +breast cancers. Bazedoxifene (BZA) is a potent antiestrogen that is clinically approved for use in hormone replacement therapies. We found that BZA possesses improved inhibitory potency against the Y537S and D538G ERα mutants compared to tamoxifen and has additional inhibitory activity in combination with the CDK4/6 inhibitor palbociclib. In addition, comprehensive biophysical and structural biology studies show BZA’s selective estrogen receptor degrading (SERD) properties that override the stabilizing effects of the Y537S and D538G ERα mutations.

1 March 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
TSThomas E. Speltz
Thomas E. Speltz
SFSean W. Fanning
Sean W. Fanning
CMChristopher G. Mayne
Christopher G. Mayne
CFColin Fowler
Colin Fowler
ETEmad Tajkhorshid
Emad Tajkhorshid
TMTerry W. Moore
Terry W. Moore

18 June 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Sean FanningSean Fanning
Sean Fanning
LHL. Hodges-Gallagher
L. Hodges-Gallagher
DMD. C. Myles
D. C. Myles
RSR. Sun
R. Sun
CFC. E. Fowler
C. E. Fowler
PKP. J. Kushner
P. J. Kushner
Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer. Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates. Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay. We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model. Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.

18 August 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HMHelen S. Mueller
Helen S. Mueller
CFColin E. Fowler
Colin E. Fowler
SDSimona Dalin
Simona Dalin
EMEnrico Moiso
Enrico Moiso
TUTee Udomlumleart
Tee Udomlumleart
JLJacqueline A. Lees
Jacqueline A. Lees
Significance: Resistance to therapeutics is a challenge when treating cancer patients. Cancer can become resistant to therapies in distinct, unpredictable ways. Therefore, it is important to understand how resistance occurs to enable development of second-line or combination treatment strategies. This study develops cells that are resistant to inhibitors of protein arginine methyltransferase 5 (PRMT5), which is up-regulated in many cancers and being targeted in current clinical trials. We show that resistant lung adenocarcinoma cells are now sensitive to the widely used chemotherapy, paclitaxel, and identify a single gene, Stmn2 , that is responsible for both the resistance to inhibitors of PRMT5 and the collateral sensitivity to paclitaxel. Our data suggest that combined treatment with PRMT5 inhibitors and taxanes could be a success.

20 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CFColin E. Fowler
Colin E. Fowler
NONatalie A. O’hearn
Natalie A. O’hearn
GSGriffin J. Salus
Griffin J. Salus
ASArundeep Singh
Arundeep Singh
PBPaul L. Boutz
Paul L. Boutz
JLJacqueline A. Lees
Jacqueline A. Lees
Summary: Protein arginine methyltransferase 5 (PRMT5) is a promising cancer target, yet it’s unclear which PRMT5 roles underlie this vulnerability. Here, we establish that PRMT5 inhibition induces a special class of unspliced introns, called detained introns (DIs). To interrogate the impact of DIs, we depleted CLNS1A, a PRMT5 cofactor that specifically enables Sm protein methylation. We found that many, but not all, cell lines are CLNS1A-dependent and established that loss of viability is linked to loss of Sm protein methylation and DI upregulation. Finally, we discovered that PRMT5-regulated DIs, and the impacted genes, are highly conserved across human, and also mouse, cell lines but display little interspecies conservation. Despite this, human and mouse DIs have convergent impacts on proliferation by affecting essential components of proliferation-regulating complexes. Together, these data argue that the PRMT5-splicing axis, including appropriate DI splicing, underlies cancer’s vulnerability to PRMT5 inhibitors.

23 April 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
Sean FanningSean Fanning
Sean Fanning
RJRinath Jeselsohn
Rinath Jeselsohn
VDVenkatasubramanian Dharmarajan
Venkatasubramanian Dharmarajan
CMChristopher G. Mayne
Christopher G. Mayne
MKMostafa Karimi
Mostafa Karimi
GGGeoffrey Greene
Geoffrey Greene
Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in the ESR1 (estrogen receptor alpha (ERα) gene ligand-binding domain (LBD) represent a recognized mechanism of acquired resistance. Antiestrogens with improved efficacy versus tamoxifen might overcome the resistant phenotype in ER+ breast cancers. Bazedoxifene (BZA) is a potent antiestrogen that is clinically approved for use in hormone replacement therapies. We find BZA possesses improved inhibitory potency against the Y537S and D538G ERα mutants compared to tamoxifen and has additional inhibitory activity in combination with the CDK4/6 inhibitor palbociclib. In addition, comprehensive biophysical and structural biology studies show that BZA’s selective estrogen receptor degrading (SERD) properties that override the stabilizing effects of the Y537S and D538G ERα mutations. Significance: Bazedoxifene (BZA) is a potent orally available antiestrogen that is clinically approved for use in hormone replacement therapy (DUAVEE). We explore the efficacy of BZA to inhibit activating somatic mutants of ERα that can arise in metastatic breast cancers after prolonged exposure to aromatase inhibitors or tamoxifen therapy. Breast cancer cell line, biophysical, and structural data show that BZA disrupts helix 12 of the ERα ligand binding domain to achieve improved potency against Y537S and D538G somatic mutants compared to 4-hydroxytamoxifen.